| 321.14 -1.66 (-0.51%) | 09-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 379.38  |
1-year : | 383.8 |
| Resists | First : | 324.81 |
Second : | 328.6 |
| Pivot price | 323.89 |
|||
| Supports | First : | 318.7 |
Second : | 265.15 |
| MAs | MA(5) : | 322.3 |
MA(20) : | 324.43 |
| MA(100) : | 322.34 |
MA(250) : | 310.66 |
|
| MACD | MACD : | 0 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 21.5 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 362.41 | Low : | 221.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PEN ] has closed above bottom band by 17.0%. Bollinger Bands are 5.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 324.32 - 325.95 | 325.95 - 327.3 |
| Low: | 317.32 - 319.07 | 319.07 - 320.51 |
| Close: | 318.8 - 321.53 | 321.53 - 323.77 |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Fri, 28 Aug 2026
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Thu, 13 Aug 2026
Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc - Stock Titan
Tue, 28 Jul 2026
Penumbra, Inc. Revenue Breakdown – NYSE:PEN - TradingView
Sat, 18 Jul 2026
Penumbra Inc. (PEN) Holds Steady Near Resistance as Market Consolidates - McClellan Summation - vinanet.vn
Wed, 06 May 2026
Penumbra, Inc. Reports First Quarter 2026 Financial Results - PR Newswire
Wed, 25 Feb 2026
Penumbra Inc. (PEN) Releases Q4 2025 Earnings: Revenue and EPS Beat, Strong YoY Growth - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 88.3 (%) |
| Shares Short | 1,840 (K) |
| Shares Short P.Month | 2,040 (K) |
| EPS | 4.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.86 |
| Profit Margin | 10.6 % |
| Operating Margin | 10.5 % |
| Return on Assets (ttm) | 6.4 % |
| Return on Equity (ttm) | 11.3 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 25.89 |
| Sales Per Share | 38.08 |
| EBITDA (p.s.) | 5.18 |
| Qtrly Earnings Growth | -23.5 % |
| Operating Cash Flow | 278 (M) |
| Levered Free Cash Flow | 161 (M) |
| PE Ratio | 79.15 |
| PEG Ratio | 4.4 |
| Price to Book value | 8.26 |
| Price to Sales | 8.43 |
| Price to Cash Flow | 45.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|